Europe Multiple Myeloma Therapeutics Market Share, Growth, Trends, and Forecasts
Europe Multiple Myeloma Therapeutics Market was worth $1.8 billion in 2016 and estimated to be growing at a CAGR of 4.58%, to reach $2.25 billion by 2021
(EMAILWIRE.COM, January 29, 2018 ) The Europe Multiple Myeloma Therapeutics Market was worth $1.8 billion in 2016 and estimated to be growing at a CAGR of 4.58%, to reach $2.25 billion by 2021. Europe is the second largest market among regions after North America.
The Multiple Myeloma (MM) market is presently dominated by Velcade and Revlimid, and the market is set to experience considerable growth between 2016 and 2021. As multiple myeloma is mostly irredeemable and is regularly characterised by a cycle of reduction and relapse, there is an acute need for new treatments for patients that work in distinctive and innovative ways.
Browse For market Segmentation and TOC @ https://marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/
Improved investments in R&D in the pharmaceutical area, absence of healing drugs for blood diseases and the introduction of advanced drugs have fuelled the growth of multiple myeloma therapeutics market. Therapies such as radiation therapy, chemotherapy, physiotherapy, and biological therapy have huge potential to outgrowth the market. The patent terminations of some bestselling drugs have obstructed the growth of the market.
Get Free Sample Report @ https://marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/request-sample
The Europe Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.
Inquire before buying @ https://marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/inquire
Based on geography the market is analysed under various regions namely, Germany, Italy, France, Spain and U.K. France is the largest market for multiple myeloma therapeutics in the European region while Italy and Spain are estimated to grow at highest CAGR.
Buy now @ https://marketdataforecast.com/cart/buy-now/europe-multiple-myeloma-therapeutics-market-860/
Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
The Multiple Myeloma (MM) market is presently dominated by Velcade and Revlimid, and the market is set to experience considerable growth between 2016 and 2021. As multiple myeloma is mostly irredeemable and is regularly characterised by a cycle of reduction and relapse, there is an acute need for new treatments for patients that work in distinctive and innovative ways.
Browse For market Segmentation and TOC @ https://marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/
Improved investments in R&D in the pharmaceutical area, absence of healing drugs for blood diseases and the introduction of advanced drugs have fuelled the growth of multiple myeloma therapeutics market. Therapies such as radiation therapy, chemotherapy, physiotherapy, and biological therapy have huge potential to outgrowth the market. The patent terminations of some bestselling drugs have obstructed the growth of the market.
Get Free Sample Report @ https://marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/request-sample
The Europe Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.
Inquire before buying @ https://marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/inquire
Based on geography the market is analysed under various regions namely, Germany, Italy, France, Spain and U.K. France is the largest market for multiple myeloma therapeutics in the European region while Italy and Spain are estimated to grow at highest CAGR.
Buy now @ https://marketdataforecast.com/cart/buy-now/europe-multiple-myeloma-therapeutics-market-860/
Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
Contact Information:
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results